mRNA vaccine

Stabil5 Meldungen3 QuellenZuletzt aktualisiert: 6 sa önce

Neueste Meldungen

AI-driven cancer treatment for dog Rosie highlights regulatory hurdles in Australia

An Australian dog named Rosie received an AI-assisted mRNA vaccine that significantly shrunk her tumors, extending her life. Scientists at UNSW used AI to process genetic data, fast-tracking treatment design from years to months. However, outdated regulatory frameworks in Australia are seen as a major obstacle to adopting such AI-driven precision medicine for humans.

ABC Top Stories

In Entwicklung

Gesundheit·7 sa önceKI-Zusammenfassung

AI-driven cancer treatment in dogs highlights regulatory hurdles for Australian medicine

A dog named Rosie's cancer treatment, aided by AI, has demonstrated the potential of personalized medicine. However, outdated regulations in Australia are hindering the adoption of such advanced AI-driven therapies for both humans and animals.

ABC Top Stories

In Entwicklung

Gesundheit·6 sa önceKI-Zusammenfassung

AI-powered cancer treatment for dog Rosie highlights Australia's regulatory hurdles

An Australian dog named Rosie received a life-extending cancer treatment developed with AI, but scientists warn outdated regulations are hindering Australia's potential to lead in AI-driven precision medicine.

ABC Top Stories

New mRNA vaccine shows promise in reducing skin cancer recurrence

In Entwicklung

Gesundheit·03.06.2026KI-Zusammenfassung

New mRNA vaccine shows promise in reducing skin cancer recurrence

A new mRNA vaccine, Intessemiran Autogen, combined with immunotherapy, has shown a 49% reduction in skin cancer recurrence or death in Stage III/IV patients. The vaccine analyzes tumor mutations to train the immune system.

الشرق الأوسط

Personalized mRNA Vaccine Shows Promise in Melanoma Trial

In Entwicklung

Gesundheit·01.06.2026KI-Zusammenfassung

Personalized mRNA Vaccine Shows Promise in Melanoma Trial

A personalized mRNA vaccine combined with Keytruda significantly reduced the risk of melanoma recurrence and death in a clinical trial. The therapy, which trains T cells to target unique tumor neoantigens, showed 68.8% of patients remained cancer-free after five years, compared to 49.1% with Keytruda alone.

NPR News